co-Trimoxazole in Zambian Infants (TZI)
赞比亚婴儿中的复方新诺明 (TZI)
基本信息
- 批准号:6816630
- 负责人:
- 金额:$ 12.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-01 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AfricanPlasmodium falciparumPneumocystis pneumoniaclinical researchcommunicable disease controlcommunicable disease transmissioncomorbiditydrug adverse effecthealth care policyhealth care service evaluationhealth services research taghuman immunodeficiency virushuman subjecthuman therapy evaluationinfant human (0-1 year)longitudinal human studymalariamultidrug resistanceoutcomes researchpatient oriented researchpediatricsprotozoal infectionpyrimethaminesulfamethoxazoletrimethoprim
项目摘要
DESCRIPTION (provided by applicant): Current World Health Organization guidelines recommend that infants exposed to HIV at birth should receive cotrimoxazole (TMZ-SMZ) as empiric prophylaxis against Pneumocystis pneumonia for one year without confirmation of H1V infection. However, 70-90% of exposed infants will not become HIV positive but would still take prophylaxis presumptively for one year. CoTrimoxazole in Zambian Infants (TZI) is a three year prospective study measuring population level effects of the WHO's proposal on common pediatric infectious diseases. TZI is funded by USAID and has been actively recruiting patients since July 1, 2003. TZI-MALARIA is a nested case control study within TZI focusing on TMP-SMZ's impact on infant malaria rates, drug resistance, and its effect on the acquistion of malaria immunity during infancy. TZI-MALARIA asks three questions: 1) Will TMP-SMZ exposure reduce rates of asymptomatic parasitemia and clinical malaria during the period of prophylaxis? 2) Will former recipients ofprophylaxis experience higher than expected rates of asymptomatic parasitemia and clinical malaria in the monthsfollowing the cessation of TMP-SMZ prophylaxis? 3) Will TMP-SMZ exposure increase rates of resistance to sulfadoxine-pyrimethamine, a leading antimalarial that is cross-tolerant with TMP-SMZ? These questions will be answered by comparing cumulative rates of malaria during and after the period of prophyalxis, and conducting genetic analsis for SP-resistance markers as a comparison between two groups of infants: Cases - infants exposed to HIV at birth and receiving prophylaxis (but later proven HIV negative at 12 months); and Controls - temporally and geographically matched HIV-unexposed, HIV negative infants, not receiving TMP-SMZ prophylaxis. TZI-MALARIA constitutes the core activity of a five year K23 career development plan. This program integrates class work, mentored research, practical field experience, additional project development, teaching, and other activities derived from the academic environment of Boston University's School of Public Health and my parent organization, the Center for International Health and Development.
描述(由申请人提供):目前世界卫生组织的指南建议,出生时接触艾滋病毒的婴儿应接受复方新诺明(TMZ-SMZ)作为预防肺孢子虫肺炎的经验性药物,为期一年,无需确认H1V感染。然而,70%-90%的受感染婴儿不会成为艾滋病毒阳性,但仍将推定接受一年的预防性治疗。赞比亚婴儿中的复方新诺明(TZI)是一项为期三年的前瞻性研究,衡量世界卫生组织关于常见儿科传染病的建议对人群水平的影响。TZI由美国国际开发署资助,自2003年7月1日以来一直在积极招募患者。TZI-疟疾是TZI内的一项嵌套病例对照研究,重点关注TMP-SMZ对婴儿疟疾发病率、耐药性的影响,以及它对婴儿疟疾免疫获得的影响。TZI-疟疾提出三个问题:1)接触TMP-SMZ是否会降低预防期间的无症状寄生虫血症和临床疟疾的发生率?2)在停止TMP-SMZ预防后的几个月里,以前接受预防的人是否会经历比预期更高的无症状寄生虫血症和临床疟疾的发生率?3)TMP-SMZ暴露是否会增加对磺胺多辛-乙胺嘧啶的耐药率?这些问题将通过比较疟疾在预防期间和预防后的累积率,并对SP耐药标记进行遗传分析,作为两组婴儿之间的比较:病例-出生时接触艾滋病毒并接受预防(但后来被证明在12个月时艾滋病毒阴性)的婴儿;以及对照--时间和地理上匹配的未接触艾滋病毒的、艾滋病毒阴性的婴儿,没有接受TMP-SMZ预防。Zzi疟疾是K23职业发展五年计划的核心活动。这项计划整合了课堂作业、指导研究、实践实地经验、额外的项目开发、教学和其他活动,这些活动来自波士顿大学公共卫生学院和我的上级组织国际卫生与发展中心的学术环境。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher J GILL其他文献
Christopher J GILL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher J GILL', 18)}}的其他基金
Mobile bedside ultrasound for the diagnosis of pediatric pneumonia in resource limited settings
移动床边超声诊断资源有限环境中的小儿肺炎
- 批准号:
10246667 - 财政年份:2019
- 资助金额:
$ 12.74万 - 项目类别:
SAMIPS-NPC: Southern Africa Mother Infant Pertussis Study, Nasopharyngeal Carriage
SAMIPS-NPC:南部非洲母婴百日咳研究,鼻咽运输
- 批准号:
9470216 - 财政年份:2017
- 资助金额:
$ 12.74万 - 项目类别:
SAMIPS-NPC: Southern Africa Mother Infant Pertussis Study, Nasopharyngeal Carriage
SAMIPS-NPC:南部非洲母婴百日咳研究,鼻咽运输
- 批准号:
9761440 - 财政年份:2017
- 资助金额:
$ 12.74万 - 项目类别:
mCME Delivering continuing medical education to community health workers using cell phones
mCME 使用手机向社区卫生工作者提供继续医学教育
- 批准号:
8806170 - 财政年份:2014
- 资助金额:
$ 12.74万 - 项目类别:
mCME Delivering continuing medical education to community health workers using cell phones
mCME 使用手机向社区卫生工作者提供继续医学教育
- 批准号:
8926486 - 财政年份:2014
- 资助金额:
$ 12.74万 - 项目类别:
mCME Delivering continuing medical education to community health workers using cell phones
mCME 使用手机向社区卫生工作者提供继续医学教育
- 批准号:
9117774 - 财政年份:2014
- 资助金额:
$ 12.74万 - 项目类别:
相似海外基金
Genomics and sero-epidemiology of Plasmodium falciparum malaria in a pre-elimination setting
消灭前环境中恶性疟原虫疟疾的基因组学和血清流行病学
- 批准号:
10666280 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum
阐明青蒿素诱导恶性疟原虫休眠的机制
- 批准号:
10742385 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Investigating the role of SCF ubiquitin ligases during sexual development of Plasmodium falciparum
研究 SCF 泛素连接酶在恶性疟原虫性发育过程中的作用
- 批准号:
MR/W025566/1 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Research Grant
Rotation 1: Investigating the role(s) of the putative FANCJ helicase in the malaria parasite Plasmodium falciparum
第 1 轮:研究假定的 FANCJ 解旋酶在疟原虫恶性疟原虫中的作用
- 批准号:
2886902 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Studentship
Exploring the role of phosphoinositides in the trafficking of proteins to the apical complex in the malaria parasite Plasmodium falciparum.
探索磷酸肌醇在疟原虫恶性疟原虫顶复合体蛋白质运输中的作用。
- 批准号:
495093 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Operating Grants
DDT-BMQ-0000100 Qualification of the Plasmodium falciparum 18S rRNA biomarker for malaria-endemic controlled human malaria infection studies
DDT-BMQ-0000100 疟疾流行控制人类疟疾感染研究中恶性疟原虫 18S rRNA 生物标志物的鉴定
- 批准号:
10836140 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Defining molecular determinants of Plasmodium falciparum hematopoietic infection using single cell profiling and genetics
使用单细胞分析和遗传学定义恶性疟原虫造血系统感染的分子决定因素
- 批准号:
EP/Y003705/1 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Fellowship
Detailed mechanism of trafficking proteins involved in the virulence of Plasmodium falciparum
恶性疟原虫毒力中涉及的运输蛋白的详细机制
- 批准号:
22KF0032 - 财政年份:2023
- 资助金额:
$ 12.74万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Étude du rôle de la phosphatase de phosphoinositides SAC1 dans le trafic de protéines au complexe apical chez le parasite de la malaria Plasmodium falciparum
疟疾疟原虫顶端寄生虫复合物中磷酸肌醇磷酸酶 SAC1 的研究
- 批准号:
486094 - 财政年份:2022
- 资助金额:
$ 12.74万 - 项目类别:
Studentship Programs
In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine
体外生物反应器生产具有复制能力的转基因晚期肝阶段恶性疟原虫子孢子疫苗
- 批准号:
10547414 - 财政年份:2022
- 资助金额:
$ 12.74万 - 项目类别: